Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis

Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This analysis characterized the pharmacokinetics (PK) of tofacitinib in adult patients with active PsA and evaluated the impact of covariates (baseline characteristics) on the disposition of tofa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Rujia, Deng, Chenhui, Wang, Qiang, Kanik, Keith S., Nicholas, Timothy, Menon, Sujatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704728/
https://www.ncbi.nlm.nih.gov/pubmed/31319908
http://dx.doi.org/10.5414/CP203516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704728/
https://www.ncbi.nlm.nih.gov/pubmed/31319908
http://dx.doi.org/10.5414/CP203516

Ejemplares similares